Remove Blogging Remove Develop Remove Study Remove Thousand Oaks
article thumbnail

Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More

Xconomy

Who will break free of the pack of companies developing drugs meant to prevent migraines? —Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen.

Avalon 40
article thumbnail

Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More

Xconomy

—More developments arrived this week in the Sarepta Therapeutics (NASDAQ: SRPT ) saga. —On the positive side, Thousand Oaks, CA-based Amgen (NASDAQ: AMGN ) released an overview of Phase 2 data that showed its migraine prevention drug, erenumab, is keeping pace with rival drugs in a heated race to market.